Intestinal resection; Fatigue; This spontaneous case was reported by a consumer and describes the occurrence of INTESTINAL RESECTION (Intestinal resection) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.    No Medical History information was reported.   In 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) Citrate free. In 2021, the patient experienced INTESTINAL RESECTION (Intestinal resection) (seriousness criterion medically significant) and FATIGUE (Fatigue). At the time of the report, INTESTINAL RESECTION (Intestinal resection) and FATIGUE (Fatigue) outcome was unknown.            No concomitant medication was provided by reporter.  The patient had surgery to remove part of her intestine. The patient took Moderna COVID-19 vaccine in 2021 and she had COVID vaccine fatigue. it was unknown if patient was enrolled in a COVID -19 vaccine trial.  No treatment medication was provided by reporter.  Company Comment: This spontaneous case was reported by a consumer concerning a 35 year old female patient with no medical history reported, with reported  Co-suspect non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.  On an unknown date with vaccination with the 1st , 2nd and 3rd dose of mRNA-1273 vaccine ,  this patient experienced Serious ( Medically significant ) , unexpected event of Intestinal resection and  non-serious , expected event of fatigue . Onset latency of  events cannot be assessed since the onset date of  the events and the dates of vaccination were not provided.  The patient had surgery to remove part of her intestine and the patient took Moderna COVID-19 vaccine in 2021 and she had COVID vaccine fatigue. Other details surrounding the events like treatment information  or  if any laboratories /diagnostic procedures done were not reported. Outcome of the events was reported as unknown. The reported Co-suspect drug ADALIMUMAB (HUMIRA) is considered as a confounder for all of the events. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This spontaneous case was reported by a consumer concerning a 35 year old female patient with no medical history reported, with reported  Co-suspect non-company product ADALIMUMAB (HUMIRA) for Crohn's disease.  On an unknown date with vaccination with the 1st , 2nd and 3rd dose of mRNA-1273 vaccine ,  this patient experienced Serious ( Medically significant ) , unexpected event of Intestinal resection and  non-serious , expected event of fatigue . Onset latency of  events cannot be assessed since the onset date of  the events and the dates of vaccination were not provided.  The patient had surgery to remove part of her intestine and the patient took Moderna COVID-19 vaccine in 2021 and she had COVID vaccine fatigue. Other details surrounding the events like treatment information  or  if any laboratories /diagnostic procedures done were not reported. Outcome of the events was reported as unknown. The reported Co-suspect drug ADALIMUMAB (HUMIRA) is considered as a confounder for all of the events. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.